NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Cornell's Nanoparticle Breakthrough in Cancer Immunotherapy
TL;DR
Cornell's nanoparticles offer a breakthrough advantage by supercharging immunotherapy to treat resistant cancers more effectively than current approaches.
The nanoparticles work by altering hostile tumor conditions and amplifying existing immunotherapy drugs in a dual-capacity mechanism.
This development makes the world better by providing new hope for treating resistant cancers and improving patient outcomes.
Cornell researchers created unexpected dual-capacity nanoparticles that fundamentally change how we approach cancer immunotherapy.
Found this article helpful?
Share it with your network and spread the knowledge!
Cornell researchers have developed nanoparticles that can supercharge cancer immunotherapy by fundamentally altering hostile tumor conditions while amplifying the potency of existing immunotherapy drugs.
This represents a breakthrough approach to treating resistant cancers that don't respond well to current immunotherapy treatments.
The nanoparticles work in a dual capacity: they alter hostile tumor conditions and amplify the effectiveness of existing immunotherapy drugs.
The particles were developed by researchers at Cornell University.
The content mentions Calidi Biotherapeutics Inc. (NYSE American: CLDI) as an entity leveraging oncolytic viruses for similar purposes.
You can read more at the Cornell University news article linked in the content or visit the TinyGems website for additional coverage.
TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, and it's publishing this content as part of its mission to provide breaking news and insightful content about companies with potential.
You can receive SMS alerts by texting 'Gems' to 888-902-4192 (U.S. Mobile Phones Only) or visit their website at https://www.TinyGems.com.
TinyGems provides: (1) access to wire solutions via InvestorWire, (2) article syndication to 5,000+ outlets, (3) enhanced press release services, (4) social media distribution, and (5) tailored corporate communications solutions.
You can contact TinyGems at Editor@TinyGems.com, call 512.354.7000, or visit their website at https://www.TinyGems.com.
Curated from InvestorBrandNetwork (IBN)
